02.27.25 -- Inside Gene Therapies For Cardiac Care With Tenaya Therapeutics' Faraz Ali

A consistent cell therapy manufacturing process starts with identifying the Critical Process Parameters (CPPs) and implementing the appropriate controls.

Cell therapy has emerged as a powerful tool for addressing critical medical challenges, but its rapid evolution necessitates a clear regulatory framework and consistent terminology.

Find out how a closed-system approach is unique and how implementing this approach could improve your process development and manufacturing.

Read more about trends in the biologics market that could impact the lifecycle strategies for your drug product and steps you can take around drug packaging early in development.

This presentation emphasizes the significance of minimizing particulate contamination in pharmaceutical and biopharmaceutical products produced through the use of single-use systems.

Learn about a solution for streamlining workflow in novel biologics while collecting quality data, by combining single-use microbioreactors with advanced automation and analytical platforms.

Take a closer look into research aimed at enhancing the cryogenic freezing process of the mammalian CHO-K1 cell line using a controlled-rate liquid nitrogen freezer.

Discover NIH's innovative solution to clinical-stage viral vector production: See how two mobile cGMP facilities deliver adaptability and compliance to Bethesda's National Institute of Health.

AAV therapies require high quality and high titers of viral genomes per dosage, prompting the need for a more efficient AAV manufacturing method to reduce overall costs.

Explore data resulting from an initial high-throughput screening experiment carried out to broadly evaluate anion exchange resins that exhibited high LVV recovery.

Evaluate the performance of a cell harvesting system using data on the titer recovery and turbidity during the downstream processing and clarification of lentiviral vectors.